overall survival (OS) - IPCW
Fig. 3 · Panel A
Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Rachel E Sanborn, Caicun Zhou, Ke-Jing Tang, Byoung Chul Cho, Susanna Cheng, Sanjay Popat, Akira Ono, Shun Lu, Margarita Majem, Andres Aguilar, Maria Del Rosario Garcia Campelo, Hidetoshi Hayashi, Kang-Yun Lee, Se-Hoon Lee, Angelo Delmonte, Jorge Alatorre-Alexander, Gary Richardson, Victor Santos, Christophe Dooms, Joshua K Sabari, Catherine A Shu, Nicolas Girard, Aaron S Mansfield, Keunchil Park, Yichuan Xia, Archan Bhattacharya, Nasuh Buyukkaramikli, Nolen Perualila, Joris Diels, Sandip Acharya, Conor Chandler, Irina Proskorovsky, Lindsay Dearden, Honeylet Wortman-Vayn, Parthiv J Mahadevia, Roland E Knoblauch, Trishala Agrawal, Mahadi Baig, Enriqueta Felip
Target Oncol 20(6) 979-989
BACKGROUND: In the PAPILLON study, first-line amivantamab-chemotherapy in epidermal growth factor receptor (EGFR) exon 20 insertion-mutated non-small cell lung cancer demonstrated significantly prolonged progression-free survival and favorable overall survival over chemotherapy; a consistent benefit was also observed across some secondary endpoints. However, the complete clinical benefit of first-line amivantamab-chemotherapy is not fully understood, nor is the survival advantage in the presence of per-protocol crossover from chemotherapy to amivantamab after progression. OBJECTIVE: We aimed to assess time to treatment discontinuation (TTD) and time to subsequent therapy (TTST), at the time of primary analysis for progression-free survival, and the effect of the crossover design on overall survival at the time of interim analysis. METHODS: In the phase III PAPILLON study, 308 participants were randomized (amivantamab-chemotherapy, n = 153; chemotherapy, n = 155). Intravenous amivantamab was administered every 3 weeks. Chemotherapy was administered as carboplatin for four cycles and pemetrexed until disease progression. TTD and TTST were evaluated using Kaplan-Meier and Cox proportional hazards models. Crossover-adjusted survival estimates were generated using three established statistical methods. RESULTS: At a median follow-up of 14.9 months, median TTD was 13.2 versus 7.5 months for amivantamab-chemotherapy versus chemotherapy (hazard ratio [HR] 0.38 [95% confidence interval 0.28-0.51]; nominal p < 0.0001). Median TTST was 17.7 versus 9.9 months (HR 0.35 [95% confidence interval 0.25-0.49]; nominal p < 0.0001). A total of 65/155 participants crossed over from chemotherapy to amivantamab after progression. The crossover-adjusted overall survival continued to demonstrate a favorable survival benefit for amivantamab-chemotherapy versus chemotherapy with HRs of 0.52-0.60, which is more pronounced than the planned interim intention-to-treat overall survival (HR of 0.67; 95% confidence interval 0.42-1.09). CONCLUSIONS: In PAPILLON, TTD and TTST were substantially longer for amivantamab-chemotherapy versus chemotherapy at primary analysis (cut-off on 3 May 2023). Crossover-adjusted analyses of the planned interim overall survival demonstrated a greater benefit for amivantamab-chemotherapy versus chemotherapy, further supporting amivantamab-chemotherapy as the first-line standard of care in EGFR exon 20 insertion-mutated non-small cell lung cancer. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04538664.
1 个 Figure · 3 个 KM 面板
Fig. 3 Crossover-adjusted overall survival (OS) for a inverse probability of censoring weighting (IPCW), b two-stage estimation (TSE), and c rank-preserving structural failure time (RPSFT). a P value calculated by assuming log (hazard ratio [HR]) is normally distributed. CI confidence interval, ITT intention-to-treat, mo months
Fig. 3 · Panel A
Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel B
Panel B 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel C
Panel C 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。